Kura Oncology Stock News

Shares of Kura Oncology Inc. KURA, -1.24% dropped nearly 6% in the aftermarket Tuesday after the biotech said it plans to sell $100 million worth of shares, plus an option for underwriters to buy addi

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Pete De Spain - SVP, IR & Corporate Communications Troy Wilson - Chairman, CEO & Presid

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o

Investors looking for help finding the best under-the-radar stocks may have a new ally: the AI chatbot. Using the prompt “publicly traded companies that may be on the cusp of breaking out in popula

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations and Corporate Communic

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Stocks are showing signs of life in 2023. And if you have a tolerance for risk and are willing to look for stocks to trade, the small-cap sector is one area to find stocks to watch.

Kura Oncology, Inc. has two assets, and both produced decent data. Each asset has its own set of problems.

The stock price of Kura Oncology (KURA) fell by over 13% intraday today. This is why.

Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Corporate Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - Preside

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.